377 related articles for article (PubMed ID: 24661226)
1. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
Lin HC; Hsu YT; Kachingwe BH; Hsu CY; Uang YS; Wang LH
J Clin Pharm Ther; 2014 Aug; 39(4):354-60. PubMed ID: 24661226
[TBL] [Abstract][Full Text] [Related]
2. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
3. Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan.
Yeh HT; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2012 Apr; 34(4):885-93. PubMed ID: 22440193
[TBL] [Abstract][Full Text] [Related]
4. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
[TBL] [Abstract][Full Text] [Related]
5. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
6. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
Koro C; Barrett S; Qizilbash N
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):485-92. PubMed ID: 17192841
[TBL] [Abstract][Full Text] [Related]
7. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.
Govindarajan R; Ratnasinghe L; Simmons DL; Siegel ER; Midathada MV; Kim L; Kim PJ; Owens RJ; Lang NP
J Clin Oncol; 2007 Apr; 25(12):1476-81. PubMed ID: 17442990
[TBL] [Abstract][Full Text] [Related]
9. Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus.
Sun GE; Wells BJ; Yip K; Zimmerman R; Raghavan D; Kattan MW; Kashyap SR
Diabetes Obes Metab; 2014 Mar; 16(3):276-83. PubMed ID: 24199848
[TBL] [Abstract][Full Text] [Related]
10. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
11. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.
Toprani A; Fonseca V
Diabetes Obes Metab; 2011 Mar; 13(3):276-80. PubMed ID: 21205120
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan.
Chiu CC; Huang CC; Chen YC; Chen TJ; Liang Y; Lin SJ; Chen JW; Leu HB; Chan WL
Intern Med; 2013; 52(9):939-46. PubMed ID: 23648711
[TBL] [Abstract][Full Text] [Related]
14. Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner.
Tsai MJ; Yang CJ; Kung YT; Sheu CC; Shen YT; Chang PY; Huang MS; Chiu HC
Lung Cancer; 2014 Nov; 86(2):137-43. PubMed ID: 25267165
[TBL] [Abstract][Full Text] [Related]
15. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
16. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
17. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
18. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan.
Lai SW; Muo CH; Liao KF; Sung FC; Chen PC
Am J Gastroenterol; 2011 Sep; 106(9):1697-704. PubMed ID: 21577242
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes.
Tseng CH
Metabolism; 2014 Aug; 63(8):1049-55. PubMed ID: 24889868
[TBL] [Abstract][Full Text] [Related]
20. Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study.
Lin HC; Kachingwe BH; Lin HL; Cheng HW; Uang YS; Wang LH
Pharmacotherapy; 2014 Jan; 34(1):36-45. PubMed ID: 23864581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
